Search results for

Emma Barraclough, Hong Kong

Translation of priority documents no longer required From January 1 2006, patent applicants are no longer required to provide Korean translations of priority documents unless requested to do so by an examiner at the Korean Intellectual Property Office (KIPO) or a trial examiner at KIPO's Intellectual Property Tribunal. Applications where the deadline for submitting a Korean translation of priority documents expires on or after January 1 2006 will be subject to this new rule. As a result, foreign applicants will benefit from substantially lower patent filing costs in Korea because they will no longer need to pay translation costs.

With effect from January 1 2006, the Italian Parliament has abolished all official fees and stamp duties due in Italy on patents (including national phases of European patents), utility models and designs. The provision, which is effective immediately, relates to patents, utility models and designs filed from January 1 2006, and – as far as annual and five-year renewal fees due from January 1 2006 are concerned – to cases filed up to December 31 2005.

Recently, the Australian Federal Court considered the principles of the operation of the country's laws on the doctrine of equivalents and adopted the UK "Improver" approach.

IP concerns are increasingly likely to make or break cross-border M&A deals in China. In the second of a two-part series, Catherine Sun provides a step-by-step guide to getting it right

As many observers predicted, WTO members made little progress at their ministerial meeting in December. Does the Organization still have a role to play in setting global IP rules? Emma Barraclough reports from Hong Kong

Stéphanie Bodoni, London

As global IP chief for one of the world's largest food and beverage companies, Jackie Leimer has considerable experience of working with private practice law firms. She shares some of her insights with Sam Mamudi

MIP's annual survey of the leading IP firms covers 60 jurisdictions this year, and is the result of five months of research among IP professionals worldwide. James Nurton introduces the first part of the results, and explains how the tables have been compiled

If you are a big pharmaceutical company, spending millions of dollars to manage your intellectual property every year, you will want to find the best lawyers to advise you on prosecution and litigation matters. But as Susanne Sivborg, vice-president of global intellectual property at AstraZeneca, tells Stéphanie Bodoni, the most experienced lawyers are no good if they do not respond to her company's needs